BOOK AIOM: Cardio-Oncology 2019 – Practical Recommendations
Gori S, Barbieri E, Barni S, Bisceglia I, Ciaccio M, Coletti Moia E, Curigliano G, Inno A, Maurea N, Novo G, Roselli M, Siragusa S, Spallarossa P, Tarantini L, Tralongo P, Russo A
AIOM: Italian Association of Medical Oncology – Special Progect and management of work group cardio-oncolog 2019AIOM – AICO – ARCA – ICOS – SIAARTI – SIBioC – SIE AIOM – AICO – ARCA – ICOS – SIAARTI – SIBioC – SIE
From the introduction of the volume “Cardio-Oncology 2019: Practical Recommendations“, Stefania Gori – National President AIOM 2017-2019:
“The cardiologic evaluation of the cancer patient is an issue of growing interest for doctors and patients.
This issue has been brought to the forefront after the discovery and use of pharmacological agents that are capable of producing cardiotoxicity (above all anthracycline and anti-HER2 monoclonal antibodies) and has gained even more notoriety after the introduction of a new class of drugs (antiangiogenic, tyrosine kinase inhibitors, immunotherapies) that are also capable of causing adverse secondary effects that affect the cardiovascular system in the medium and long term.
For these reasons, an accurate evaluation of basal cardiac function during and after pharmacological treatment has become a real and true “medical need” for cancer patients. Appropriate management of this problem has been shown to prevent the appearance of cardiotoxicity, to limit the incidence and to permit continued appropriate clinical care.
In this way an appropriate cancer therapy management can be guaranteed with a better
patient outcome.”